Janux Therapeutics, Inc.
JANX
$17.11
$1.257.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.61% | 6.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.29% | 29.29% | |||
| Operating Income | 21.87% | -29.29% | |||
| Income Before Tax | 28.19% | -44.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.19% | -44.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.19% | -44.03% | |||
| EBIT | 21.87% | -29.29% | |||
| EBITDA | 22.05% | -29.67% | |||
| EPS Basic | 28.34% | -43.80% | |||
| Normalized Basic EPS | 28.32% | -43.73% | |||
| EPS Diluted | 28.34% | -43.80% | |||
| Normalized Diluted EPS | 28.32% | -43.73% | |||
| Average Basic Shares Outstanding | 0.20% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||